id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-319013-oytqcifa	Focosi, Daniele	Convalescent Plasma Therapy for COVID-19: State of the Art	2020-08-12		.txt	text/plain	7487	198	25	A proof of concept single arm multicenter interventional trial Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion Convalescent plasma treatment of severe COVID-19: a matched control study Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial Early safety indicators of COVID-19 convalescent plasma in 5,000 patients Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients COVID-19) patients with convalescent plasma Get rid of the bad first: therapeutic plasma exchange with convalescent plasma for severe COVID-19 The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure Efficacy of therapeutic plasma exchange in severe COVID-19 patients Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 Global Vaccine Business Unit on the latest on the coronavirus and Takeda Is it time to rethink UK restrictions on blood donation? Hepatitis E virus in blood components: a prevalence and transmission study in southeast England Pork products associated with human infection caused by an emerging phylotype of hepatitis E virus in England and Wales Hepatitis E risks: pigs or blood-that is the question SARS-coronavirus replication in human peripheral monocytes/macrophages Epitopes required for antibody-dependent enhancement of Ebola virus infection Antibodydependent enhancement of Ebola virus infection Influence of Fc␥RIIA and MBL polymorphisms on severe acute respiratory syndrome Immune phenotyping based on neutrophil-tolymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19 Viral kinetics and antibody responses in patients with COVID-19 Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome The potential danger of suboptimal antibody responses in COVID-19 Symptomatic SARS-CoV-2 infections display specific IgG Fc structures Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19 Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Currently available intravenous immunoglobulin (Gamunex © -C and Flebogamma © DIF) contains antibodies reacting against SARS-CoV-2 antigens High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019 ABO blood group and susceptibility to severe acute respiratory syndrome Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complementmediated inactivation Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2 Specific asparagine-linked glycosylation sites are critical for DC-SIGN-and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV) After demonstration that blood group O health care workers were less likely to become infected with SARS-CoV (137), a research group proved that anti-A blood group natural isoagglutinins (which can also be found in CP plasma from blood group O and B donors) inhibit SARS-CoV entry into competent cells (138) .	cache/cord-319013-oytqcifa.txt	txt/cord-319013-oytqcifa.txt
